Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 28, 2023 19:00 ET | Source: Alvotech

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

REYKJAVIK, Iceland, June 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
June 28, 2023 05:36 ET | Source: Liquidia Corporation

Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America

Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizerLiquidia funds $10 million...
June 22, 2023 17:45 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

Company to discontinue all NASH-related investment and restructure the Company’s operations to strengthen its focus on rare and serious liver diseasesCompany anticipates achieving profitability in...
June 21, 2023 07:00 ET | Source: Scynexis

SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK

JERSEY CITY, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
June 20, 2023 17:25 ET | Source: Bioasis Technologies Inc.

Bioasis Provides Corporate Update and Announces Suspension of Operations

NEW HAVEN, Conn., June 20, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...
June 20, 2023 09:00 ET | Source: Curia Global, Inc.

Curia通过CHOZN平台扩大细胞系开发服务范围

于纽约州奥尔巴尼, June 20, 2023 (GLOBE NEWSWIRE) -- 领先的合同研究、开发和制造组织Curia于今天宣布，已与德国默克生命科学的北美生命科学业务部门MilliporeSigma签署了一项授权协议，使Curia及其客户能够使用CHOZN®GS-/-细胞系用于生产治疗性蛋白质和抗体。根据协议，CHOZN...
June 20, 2023 09:00 ET | Source: Curia Global, Inc.

Curia Perluaskan Tawaran Pembangunan Talian Sel dengan Platform CHOZN

ALBANY, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- Curia, sebuah organisasi penyelidikan, pembangunan dan pembuatan kontrak terkemuka, hari ini mengumumkan mereka telah menandatangani perjanjian...
June 20, 2023 09:00 ET | Source: Curia Global, Inc.

Curia 擴展細胞系開發產品組合，引入 CHOZN 平台

美國紐約州雅賓利市, June 20, 2023 (GLOBE NEWSWIRE) -- 業界領先的合同研究開發製造組織 Curia 今天宣布與德國達姆施塔特 Merck KGaA 集團在北美的生命科學業務 MilliporeSigma 簽署許可協議，該協議使 Curia 及其客戶可以使用 CHOZN® GS-/- 細胞系進行治療性蛋白質和抗體的生產。按照該協議，CHOZN GS-/-...
June 20, 2023 09:00 ET | Source: Curia Global, Inc.

Curia ขยายการให้บริการการพัฒนาเซลล์ไลน์ด้วยแพลตฟอร์ม CHOZN

อัลบานี นิวยอร์ก, June 20, 2023 (GLOBE NEWSWIRE) -- Curia ซึ่งเป็นองค์กรชั้นนำด้านการวิจัย การพัฒนาและการผลิตตามสัญญา ได้ประกาศในวันนี้ว่า บริษัทได้ลงนามในข้อตกลงการอนุญาตให้ใช้สิทธิ์กับ...
June 20, 2023 09:00 ET | Source: Curia Global, Inc.

Curia erweitert Angebot für Zelllinienentwicklung mit der CHOZN-Plattform

ALBANY, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- Curia, ein führendes Auftragsforschungs-, Entwicklungs- und Produktionsunternehmen, hat heute die Unterzeichnung einer Lizenzvereinbarung mit...